PLEURAL MALIGNANT MESOTHELIOMA
Clinical trials for PLEURAL MALIGNANT MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new PLEURAL MALIGNANT MESOTHELIOMA trials appear
Sign up with your email to follow new studies for PLEURAL MALIGNANT MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a Triple-Drug combo tame mesothelioma?
Disease control OngoingThis study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tackle tough mesothelioma
Disease control OngoingThis study tests whether adding a targeted drug (anetumab ravtansine) to an immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with a specific type of mesothelioma. The targeted drug delivers chemotherapy directly to cancer cells that have a certai…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC